IFN-Gamma Expression in the Tumor Microenvironment and CD8-Positive Tumor-Infiltrating Lymphocytes as Prognostic Markers in Urothelial Cancer Patients Receiving Pembrolizumab

SIMPLE SUMMARY: Pembrolizumab, an immune checkpoint inhibitor, has shown therapeutic benefit for advanced urothelial carcinoma (aUC) patients, but only a limited population achieves a long-term response. Prediction of treatment outcomes for aUC patients receiving immune checkpoint inhibitors is a cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakatani, Toru, Kita, Yuki, Fujimoto, Masakazu, Sano, Takeshi, Hamada, Akihiro, Nakamura, Kenji, Takada, Hideaki, Goto, Takayuki, Sawada, Atsuro, Akamatsu, Shusuke, Kobayashi, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8774131/
https://www.ncbi.nlm.nih.gov/pubmed/35053427
http://dx.doi.org/10.3390/cancers14020263

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8774131/
https://www.ncbi.nlm.nih.gov/pubmed/35053427
http://dx.doi.org/10.3390/cancers14020263

Ejemplares similares